cellebrite di ltd - CLBT

CLBT

Close Chg Chg %
14.21 -0.05 -0.35%

Closed Market

14.16

-0.05 (0.35%)

Volume: 961.86K

Last Updated:

Mar 25, 2026, 4:00 PM EDT

Company Overview: cellebrite di ltd - CLBT

CLBT Key Data

Open

$14.44

Day Range

14.03 - 14.64

52 Week Range

11.76 - 20.86

Market Cap

$3.54B

Shares Outstanding

249.44M

Public Float

121.11M

Beta

1.30

Rev. Per Employee

N/A

P/E Ratio

45.63

EPS

$0.32

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

1.37M

 

CLBT Performance

1 Week
 
-0.42%
 
1 Month
 
6.52%
 
3 Months
 
-22.81%
 
1 Year
 
-26.98%
 
5 Years
 
44.12%
 

CLBT Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 7
Full Ratings ➔

About cellebrite di ltd - CLBT

Cellebrite DI Ltd. engages in the provision of digital investigative solutions for the public and private sectors, empowering organizations in mastering the complexities of legally sanctioned digital investigations by streamlining intelligence processes. Its services include training and advisory, value realization, advanced services, and technical customer support. The firm also offers software solutions and analytic tools designed to accelerate digital investigations and address the growing complexity of handling crime and security challenges in the digital era. The company was founded on April 13, 1999 and is headquartered in Petach Tikva, Israel.

CLBT At a Glance

Cellebrite DI Ltd.
94 Shlomo Shmelzer Road
Petach Tikva, HaMerkaz 4970602
Phone 972-73-394-8000 Revenue 475.68M
Industry Packaged Software Net Income 77.81M
Sector Technology Services 2025 Sales Growth 18.562%
Fiscal Year-end 12 / 2026 Employees 1,285
View SEC Filings

CLBT Valuation

P/E Current 45.633
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 57.90
Price to Sales Ratio 9.472
Price to Book Ratio 9.254
Price to Cash Flow Ratio 25.96
Enterprise Value to EBITDA 49.449
Enterprise Value to Sales 8.601
Total Debt to Enterprise Value 0.006

CLBT Efficiency

Revenue/Employee 370,175.097
Income Per Employee 60,554.864
Receivables Turnover 4.42
Total Asset Turnover 0.582

CLBT Liquidity

Current Ratio 1.54
Quick Ratio 1.516
Cash Ratio 1.182

CLBT Profitability

Gross Margin 84.197
Operating Margin 14.899
Pretax Margin 19.063
Net Margin 16.358
Return on Assets 9.516
Return on Equity 18.971
Return on Total Capital 15.348
Return on Invested Capital 18.399

CLBT Capital Structure

Total Debt to Total Equity 4.681
Total Debt to Total Capital 4.472
Total Debt to Total Assets 2.415
Long-Term Debt to Equity 3.856
Long-Term Debt to Total Capital 3.683
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Cellebrite Di Ltd - CLBT

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
270.65M 325.11M 401.20M 475.68M
Sales Growth
+9.91% +20.12% +23.41% +18.56%
Cost of Goods Sold (COGS) incl D&A
50.75M 53.23M 62.59M 75.17M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
9.19M 10.01M 10.61M 11.87M
Depreciation
6.37M 6.66M 7.26M 6.97M
Amortization of Intangibles
2.83M 3.35M 3.35M 4.90M
COGS Growth
+19.24% +4.90% +17.59% +20.10%
Gross Income
219.91M 271.88M 338.61M 400.50M
Gross Income Growth
+7.96% +23.63% +24.54% +18.28%
Gross Profit Margin
+81.25% +83.63% +84.40% +84.20%
2022 2023 2024 2025 5-year trend
SG&A Expense
216.90M 238.60M 281.48M 329.63M
Research & Development
80.62M 84.39M 98.42M 113.88M
Other SG&A
136.28M 154.21M 183.07M 215.75M
SGA Growth
+14.24% +10.00% +17.97% +17.11%
Other Operating Expense
- - - -
-
Unusual Expense
(114.90M) 119.39M 349.82M 4.39M
EBIT after Unusual Expense
117.91M (86.11M) (292.70M) 66.48M
Non Operating Income/Expense
4.08M 11.30M 18.32M 25.59M
Non-Operating Interest Income
2.34M 10.72M 18.22M 23.94M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
1.23M 753.00K 1.60M 1.40M
Interest Expense Growth
+117.55% -38.63% +112.62% -12.74%
Gross Interest Expense
1.23M 753.00K 1.60M 1.40M
Interest Capitalized
- - - -
-
Pretax Income
120.76M (75.56M) (275.98M) 90.68M
Pretax Income Growth
+46.72% -162.57% -265.24% +132.86%
Pretax Margin
+44.62% -23.24% -68.79% +19.06%
Income Tax
(45.00K) 5.54M 7.02M 12.35M
Income Tax - Current - Domestic
(2.57M) 3.01M 10.01M 10.61M
Income Tax - Current - Foreign
4.92M (2.88M) 588.00K 4.53M
Income Tax - Deferred - Domestic
(85.00K) 1.60M (3.16M) (1.56M)
Income Tax - Deferred - Foreign
(2.31M) 3.81M (417.00K) (1.22M)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - (4.69M) (513.00K)
-
Consolidated Net Income
116.11M (81.10M) (283.01M) 77.81M
Minority Interest Expense
- - - -
-
Net Income
116.11M (81.10M) (283.01M) 77.81M
Net Income Growth
+62.63% -169.85% -248.96% +127.50%
Net Margin Growth
+42.90% -24.95% -70.54% +16.36%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
116.11M (81.10M) (283.01M) 77.81M
Preferred Dividends
- - - -
-
Net Income Available to Common
116.11M (81.10M) (283.01M) 77.81M
EPS (Basic)
0.6355 -0.4265 -1.351 0.322
EPS (Basic) Growth
+28.18% -167.11% -216.76% +123.83%
Basic Shares Outstanding
182.69M 190.15M 209.47M 241.63M
EPS (Diluted)
0.5942 -0.4265 -1.351 0.3114
EPS (Diluted) Growth
+34.43% -171.78% -216.76% +123.05%
Diluted Shares Outstanding
195.39M 190.15M 209.47M 249.90M
EBITDA
12.20M 43.29M 67.73M 82.74M
EBITDA Growth
-41.44% +254.92% +56.45% +22.15%
EBITDA Margin
+4.51% +13.32% +16.88% +17.39%

Snapshot

Average Recommendation BUY Average Target Price 24.667
Number of Ratings 7 Current Quarters Estimate 0.054
FY Report Date 03 / 2026 Current Year's Estimate 0.368
Last Quarter’s Earnings 0.08 Median PE on CY Estimate N/A
Year Ago Earnings 0.31 Next Fiscal Year Estimate 0.453
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 7 7 7 6
Mean Estimate 0.05 0.07 0.37 0.45
High Estimates 0.09 0.11 0.51 0.64
Low Estimate 0.04 0.06 0.33 0.38
Coefficient of Variance 30.49 22.07 17.47 21.05

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 7 7 8
OVERWEIGHT 0 0 0
HOLD 0 0 0
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Cellebrite Di Ltd in the News